Lusutrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist. It acts selectively on the human TPO receptor and activates signal transduction pathways and thereby increases platelet levels. It was developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. It has been listed.
Lurbinectedin, also known as PM01183, is a synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. DNA minor groove-binding agent PM01183 covalently binds to residues lying in the minor groove of DNA, which may result in delayed progression through S phase, cell cycle arrest in the G2/M phase and cell death.
Luminespib, also known as AUY-922 (or NVP-AUY922), is a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Hsp90 inhibitor AUY922 has been shown to bind with high affinity to and inhibit Hsp90, resulting in the proteasomal degradation of oncogenic client proteins.
Lumateperone, also known as ITI-722 or ITI-007, is a highly potent 5HT2A antagonist for the treatment of sleep maintenance insomnia. Preclinical data has shown that ITI-722 is not sedating and should not exhibit next day hangover effects that are commonly associated with other sleep medications.
Lumasiran is a siRNA product that reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1).
Lumacaftor is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF). Lumacaftor may act to restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, the defective cell membrane protein responsible for the progression of CF. Lumacaftor defects in the CFTR protein affect the transport of chloride and other ions across cells, and lead to the accumulation of thick, sticky mucus in the lungs of patients with CF. This mucus fosters chronic infection and inflammation, and results in irreversible lung damage.
Lucidenic acid LM1, a triterpenoid compound, is obtained from medicinal fungi that are fit for consumption. Numerous biological activities have been ascertained to be associated with this compound such as anti-cancer, anti-inflammatory, and anti-fibrotic effects. The inhibition of human liver cancer and breast cancer cells are among the effects of Lucidenic acid LM1, which suggests its potential candidacy for the development of new anti-cancer drugs.
Lucidenic acid E, a triterpenoid derived from Ganoderma lucidum, exhibits potent anti-inflammatory, anti-tumor and anti-diabetic activities. Notably, it has demonstrated the ability to impede in vitro cancer cell growth, indicating its potential therapeutic value. Its hepatoprotective and antioxidant effects further increase the promise of lucidenic acid E in the treatment of liver ailments. Such multifaceted properties of this natural compound highlight its potential in the development of novel therapies.
Lucidenic acid C, an organic compound derived from the fungus Ganoderma lucidum, exhibits multifaceted pharmacological actions such as antioxidant, anti-inflammatory, immunomodulatory, and anticancer properties. Novel studies have elucidated that this naturally occurring triterpene exhibits profound inhibition of malignancy development and metastasis in cancer cells. The promising therapeutic potential of lucidenic acid C extends beyond oncology, offering a plethora of therapeutic applications in diverse pathological conditions.
Lucidenic acid B, an organic compound hailing from Ganoderma lucidum, is praised for its multifaceted biomedical properties. From combating neoplasms to alleviating inflammations, this natural triterpenoid holds great promise in treating debilitating conditions such as breast and prostate cancers and an array of inflammatory disorders.
Lucidenic acid A, a naturally occurring compound found in Ganoderma lucidum fruiting bodies, displays immense therapeutic potential. It exhibits anti-inflammatory, anti-tumor, and anti-diabetic properties as evidenced by various studies. Additionally, it significantly impacts physiological parameters such as blood pressure, cholesterol, and blood sugar. The multifaceted activities of Lucidenic acid A render it an ideal candidate for treating chronic inflammatory diseases, diabetes, and cancer.
Lubiprostone is a bicyclic fatty acid metabolite of Prostaglandin E1. It activates ClC-2 and CFTR chloride channels in the gastrointestinal tract, increasing intestinal fluid secretion. It is used in the management of idiopathic chronic constipation, and irritable bowel syndrome with constipation.
Lu AE58054 hydrochloride is an in-vitro potency and selectivity, in-vivo binding affinity and effect of the 5-HT(6)R antagonist with a Ki value of 0.83 nM.
Threoninol(Ac)-8-Octreotide is an impurity of Octreotide, which is a synthetic long-acting cyclic octapeptide used as a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin.
L-Sulforaphane is a compound with isothiocyanate group found in cruciferous vegetables such as broccoli, Brussels sprouts, and cabbages. It has been shown to regulate phase II detoxifying enzymes and induce cell cycle arrest or apoptosis in malignant cells in vitro and in vivo, thus can be potentially used as an antioxidant and anticancer agent.
LS-tetrasaccharide c is an extraordinary biomedical compound, bestowed with the exceptional ability to impede ceramide glycosyltransferase, a vital actor implicated in the relentless march of tumor propagation and metastasis.
L-rhamnulose is the eminent compound, aiding in elucidating perplexing metabolic disorders and facilitating avant-garde drug development. This saccharide derivative orchestrates an array of intricate biochemical reactions used in studying afflictions such as diabetes, obesity and the enigmatic metabolic syndrome.
L-Phe(1)-Octreotide is an impurity of Octreotide, which is a synthetic long-acting cyclic octapeptide used as a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin.
Loxoprofen Ring-opening Impurity is a degradation product of Loxoprofen, a non-selective nonsteroidal anti-inflammatory drug (NSAID) that has been effective in reducing atherosclerosis in mice by reducing inflammation.
An impurity of Loxoprofen, a non-selective nonsteroidal anti-inflammatory drug (NSAID) that has been effective in reducing atherosclerosis in mice by reducing inflammation.
The sulfate salt form of LOXO-101, also called Larotrectinib, which is an ATP-competitive inhibitor of tropomyosin receptor kinases. It was approved by FDA for the treatment of metastatic solid tumors.
Loxiglumide is an orally active, potent and selective small-molecule antagonist of the cholecystokinin receptor CCKA. It stimulates calorie intake and hunger feelings in humans. It could antagonize the CCK-induced reduction of gastric emptying in rats, accelerate the intestinal transport and accelerate the gallbladder emptying in mice. It inhibits pancreatic secretion of digestive enzymes, and also blocks CCK-induced gastric secretions and emptying.
Losmapimod is a promising new agent against cardiovascular diseases. This drug works by inhibiting p38 MAP kinases, which play an important role in the development of atherosclerosis and heart failure caused by ischemic conditions. Losmapimod did not cause an improvement in exercise tolerance or lung function, despite being well-tolerated in this COPD population. The p38 MAPK inhibitor losmapimod (GW856553) attenuates the pro-inflammatory response in humans by reducing PIC production.
Losartan is an angiotensin II receptor antagonist that competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. It promotes vasodilatation and counteracts the effects of aldosterone thus can be used as an antihypertensive.
Lorlatinib is an ATP-competitive ROS1/ALK inhibitor with potential antitumor activity. Lorlatinib binds to both ALK and ROS1 kinases, resulting in disruption of ALK- and ROS1-mediated signaling and inhibition of ALK- and ROS1-overexpressing tumor cells.
An antiretroviral medication acts as a protease inhibitor. It is a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS.
Lonafarnib is a farnesyl transferase inhibitor. Structurely, it is also a synthetic tricyclic derivative of carboxamide with antineoplastic properties. Lonarfanib binds to and inhibits farnesyl transferase, an enzyme involved in the post-translational modification and activation of Ras proteins. Ras proteins participate in numerous signalling pathways (proliferation, cytoskeletal organization), and play an important role in oncogenesis. Mutated ras proteins have been found in a wide range of human cancers.
Lomeguatrib, also known as PaTrin-2, is a potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase. Lomeguatrib is also a nontoxic low-molecular weight pseudosubstrate that has the ability to inactivate MGMT. Lomeguatrib can be used with temozolomide (TMZ) for GBM treatment.
Lodoxamide is a GPR35 agonist that has been used as a mast cell stabilizer. It can be used for topical administration into eyes indicated for allergic symptom treatment.
